# D4D Datasheet for AI-READI Dataset
# Generation Method: Claude Code Agent Deterministic
# Source: data/preprocessed/concatenated/AI_READI_preprocessed.txt (245K, 13 source files)
# Schema: src/data_sheets_schema/schema/data_sheets_schema_all.yaml
# Generated: 2025-12-16

id: https://fairhub.io/datasets/2
name: AI-READI
title: Artificial Intelligence Ready and Equitable Atlas for Diabetes Insights (AI-READI)
description: >
  The AI-READI is a flagship dataset consisting of multimodal data collected from 4,000 individuals
  with and without Type 2 Diabetes Mellitus (T2DM), harmonized across 3 data collection sites
  (Birmingham, Alabama; San Diego, California; Seattle, Washington). The dataset was designed
  with future AI/Machine Learning studies in mind, including recruitment sampling procedures
  aimed at achieving approximately equal distribution of participants across diabetes severity
  (triple-balanced by race/ethnicity, biological sex, and T2DM severity), as well as a
  multi-domain data acquisition protocol (survey data, physical measurements, clinical data,
  imaging data, wearable device data, environmental sensors, biospecimens) to enable downstream
  AI/ML analyses that may not be feasible with existing data sources such as claims or electronic
  health records data. The goal is to better understand salutogenesis (the pathway from disease
  to health) in T2DM. The study follows FAIR principles and incorporates ethical and equitable
  data collection and management practices.
page: https://fairhub.io/datasets/2
language: en
keywords:
  - Type 2 Diabetes Mellitus
  - T2DM
  - AI-READI
  - Machine Learning
  - Artificial Intelligence
  - multimodal dataset
  - harmonized data
  - multi-site study
  - salutogenesis
  - FAIR principles
  - retinal imaging
  - continuous glucose monitoring
  - wearable devices
  - biorepository
  - biospecimens
  - triple-balanced sampling
  - health equity
  - Bridge2AI
  - cross-sectional study

# Motivation
purposes:
  - id: purpose-001
    name: Understanding T2DM salutogenesis
    description: >
      Better understand salutogenesis (the pathway from disease to health) in Type 2 Diabetes
      Mellitus using a hypothesis-agnostic, harmonized, multi-domain dataset designed specifically
      for AI/ML research. The dataset aims to provide critical insights into how individuals can
      transition from diabetes toward health resilience.
  - id: purpose-002
    name: Establishing AI/ML data standards
    description: >
      Establish standards, best practices, and guidelines for collection, preparation, and
      sharing of medical/health data sets targeted for AI/ML applications. This includes
      guidance from bioethicists on ethical and equitable data collection and management
      practices, with adherence to FAIR principles.
  - id: purpose-003
    name: Addressing demographic inequities in T2DM research
    description: >
      Address the lack of racial and ethnic diversity in T2DM research by creating a dataset
      that is triple-balanced across race/ethnicity (Asian, Black, Hispanic, White), biological
      sex (male, female), and diabetes severity (no diabetes, pre-diabetes/lifestyle-controlled,
      medication-controlled, insulin-controlled).

tasks:
  - id: task-001
    name: Enable multi-domain AI/ML analyses for T2DM
    description: >
      Enable downstream AI/ML analyses across survey, clinical, imaging, wearable device,
      environmental, and biospecimen domains related to T2DM that may not be feasible with
      existing data sources such as claims or electronic health records data alone. The
      multimodal nature of the data supports complex machine learning model development.
  - id: task-002
    name: Develop unbiased AI/ML models
    description: >
      Support the development of unbiased machine learning models through balanced data
      collection across demographic groups and diabetes severity levels. The triple-balanced
      design is critical for preventing algorithmic bias in AI/ML applications.
  - id: task-003
    name: Study T2DM disease trajectories
    description: >
      Study disease trajectories and salutogenesis pathways in T2DM through cross-sectional
      analysis of participants at different disease stages, enabling pseudotime manifold
      analysis to predict disease progression and paths to health resilience.

addressing_gaps:
  - id: gap-001
    name: Lack of multimodal T2DM datasets
    description: >
      Provide a large-scale, harmonized, multi-site, multi-domain dataset enabling AI/ML
      analyses not feasible with existing sources (e.g., claims or EHR alone). With 4,000
      participants and over 10 variable domains, this is the largest publicly accessible
      dataset of its kind.
  - id: gap-002
    name: Demographic underrepresentation
    description: >
      Address demographic inequities in T2DM research by recruiting equal proportions across
      four race/ethnic groups (Asian, Black, Hispanic, White) and both biological sexes,
      improving upon many previous epidemiological studies and clinical trials that lacked
      diversity.
  - id: gap-003
    name: AI-readiness of medical datasets
    description: >
      Create a model for future AI-ready medical datasets through comprehensive metadata,
      standardized data formats, FAIR compliance, and ethical data governance practices
      that can be replicated for other health conditions.

# Creators and Contributors
creators:
  - id: creator-001
    name: Aaron Lee
    description: Contact PI/Project Leader, University of Washington, Department of Ophthalmology, Assistant Professor
  - id: creator-002
    name: Cynthia Owsley
    description: Principal Investigator, University of Alabama at Birmingham, Department of Ophthalmology and Visual Sciences
  - id: creator-003
    name: Sally L. Baxter
    description: Co-Investigator, University of California San Diego, Department of Ophthalmology
  - id: creator-004
    name: Christopher G. Chute
    description: Co-Investigator, AI-READI Consortium
  - id: creator-005
    name: Megan E. Collins
    description: Co-Investigator, AI-READI Consortium
  - id: creator-006
    name: Jeffrey C. Edberg
    description: Co-Investigator, University of Alabama at Birmingham, Department of Medicine
  - id: creator-007
    name: Kadija Ferryman
    description: Co-Investigator, AI-READI Consortium (Bioethics)
  - id: creator-008
    name: Michelle Hribar
    description: Co-Investigator, AI-READI Consortium
  - id: creator-009
    name: Samantha Hurst
    description: Co-Investigator, AI-READI Consortium
  - id: creator-010
    name: Hiroshi Ishikawa
    description: Co-Investigator, AI-READI Consortium
  - id: creator-011
    name: Cecilia S. Lee
    description: Co-Investigator, University of Washington, Department of Ophthalmology
  - id: creator-012
    name: Alvin Y. Liu
    description: Co-Investigator, AI-READI Consortium
  - id: creator-013
    name: Gerald McGwin
    description: Co-Investigator, University of Alabama at Birmingham, Departments of Ophthalmology and Epidemiology
  - id: creator-014
    name: Shannon K. McWeeney
    description: Co-Investigator, AI-READI Consortium
  - id: creator-015
    name: Camille Nebeker
    description: Co-Investigator, AI-READI Consortium
  - id: creator-016
    name: Bhavesh Patel
    description: Co-Investigator, AI-READI Consortium
  - id: creator-017
    name: Sara Jean Singer
    description: Co-Investigator, AI-READI Consortium
  - id: creator-018
    name: Michael P. Snyder
    description: Co-Investigator, AI-READI Consortium
  - id: creator-019
    name: Joseph Manuel Yracheta
    description: Co-Investigator, AI-READI Consortium
  - id: creator-020
    name: Linda M. Zangwill
    description: Co-Investigator, University of California San Diego, Department of Ophthalmology

funders:
  - id: funder-001
    name: NIH Common Fund Bridge2AI Program
    description: >
      Funded through National Institutes of Health grant OT2OD032644, administered by
      NIH Office of the Director. Additional support from grants P30DK035816 (Nutrition
      and Obesity Research Center), UL1TR003096, and Research to Prevent Blindness.
      Total funding in 2022: $5,026,499. Opportunity Number: OTA-21-008. Project dates:
      September 1, 2022 to August 31, 2025.

# Composition
instances:
  - id: instance-001
    name: Individual participants
    description: >
      Individual participants aged 40 and older with and without Type 2 Diabetes Mellitus (T2DM).
      Target enrollment is 4,000 people, triple-balanced by self-reported race/ethnicity (Asian,
      Black, Hispanic, White), T2DM severity (no diabetes, pre-diabetes/lifestyle-controlled
      diabetes, diabetes treated with oral medications or non-insulin injections, insulin-controlled
      diabetes), and biological sex (male, female). Participants must speak, read, and understand
      English. Exclusion criteria include pregnancy and type 1 diabetes.
    instance_type: >
      Human participants recruited from three health system sites (University of Alabama at
      Birmingham, University of California San Diego, University of Washington) between
      2022 and 2026.

subsets:
  - id: subset-001
    name: Public Access Dataset
    description: >
      Includes data not considered sensitive personal health information, available to the
      public for download upon agreement with a license. Contains survey data, blood and urine
      lab results, fitness activity levels, clinical measurements (e.g., monofilament and
      cognitive function testing), retinal images, ECG, blood glucose levels, and environmental
      variables such as home air quality. Available at https://fairhub.io/datasets/2.
  - id: subset-002
    name: Controlled Access Dataset
    description: >
      Includes sensitive data accessible by entering into a data use agreement. Contains
      5-digit zip code, sex, race, ethnicity, genetic sequencing data (from buffy coats),
      past health records, medications, and traffic and accident reports. Access requirements
      are being developed by the Data Access Committee.
  - id: subset-003
    name: Biorepository
    description: >
      Biobanked samples stored at UAB Center for Clinical and Translational Science (CCTS),
      including plasma, serum, buffy coats, peripheral blood mononuclear cells (PBMCs),
      PAXgene RNA, and urine. Available to researchers for future ancillary studies according
      to procedures and policies in development. Finite number of samples available.

sampling_strategies:
  - id: sampling-001
    name: Triple-balanced recruitment
    description: >
      Recruitment sampling procedures aimed at achieving approximately equal distribution of
      participants across three dimensions: (1) race/ethnicity (Asian, Black, Hispanic, White),
      (2) T2DM severity (no diabetes, pre-diabetes/lifestyle-controlled, medication-controlled,
      insulin-controlled), and (3) biological sex (male, female). This balanced design is
      critical for developing unbiased machine learning models.
    is_sample:
      - true
    is_random:
      - false
    is_representative:
      - false
    strategies:
      - Targeted recruitment to balance demographics across race/ethnicity, sex, and diabetes severity
      - Wave-based recruitment with monitoring and adjustment through under- and oversampling
      - Recruitment from electronic health records screening using ICD-10 codes (R73.09 for pre-diabetes, E11.X for T2DM)
      - Personalized invitation letters and emails with REDCap recruitment interface

subpopulations:
  - id: subpop-001
    name: Asian participants
    description: Self-reported Asian race/ethnicity, target ~1,000 participants (25% of sample)
  - id: subpop-002
    name: Black participants
    description: Self-reported Black race/ethnicity, target ~1,000 participants (25% of sample)
  - id: subpop-003
    name: Hispanic participants
    description: Self-reported Hispanic ethnicity, target ~1,000 participants (25% of sample)
  - id: subpop-004
    name: White participants
    description: Self-reported White race/ethnicity, target ~1,000 participants (25% of sample)
  - id: subpop-005
    name: No diabetes
    description: Participants without diabetes diagnosis, target ~1,000 participants (25% of sample)
  - id: subpop-006
    name: Pre-diabetes and lifestyle-controlled diabetes
    description: Participants with pre-diabetes or lifestyle-controlled diabetes, target ~1,000 participants (25% of sample)
  - id: subpop-007
    name: Medication-controlled diabetes
    description: Participants with diabetes treated with oral medications or non-insulin injections, target ~1,000 participants (25% of sample)
  - id: subpop-008
    name: Insulin-controlled diabetes
    description: Participants with insulin-controlled diabetes, target ~1,000 participants (25% of sample)

# Collection Process
collection_mechanisms:
  - id: collection-001
    name: In-person data collection visits
    description: >
      Single study encounter per participant at one of three data collection sites (Birmingham,
      San Diego, Seattle). Multi-domain protocol containing over 10 data collection domains
      performed during the visit lasting between 2.5 and 4 hours.
  - id: collection-002
    name: Electronic health record screening
    description: >
      Source population identified by screening electronic health records for patients aged
      40+ who had medical encounters between 2020-2025. ICD-10 codes used to identify T2DM
      (E11.X) and pre-diabetes (R73.09) cases.
  - id: collection-003
    name: Wave-based recruitment
    description: >
      Participants recruited in waves to facilitate efficient sampling. Composition and size
      of each wave influenced by observed participation characteristics to maintain balance
      across race/ethnicity, sex, and diabetes severity. Enrollment began July 18, 2023 and
      continues until November 30, 2026.
  - id: collection-004
    name: Home-based wearable monitoring
    description: >
      Continuous glucose monitoring (Dexcom G6, 5-minute intervals), physical activity
      monitoring (Garmin VivoSmart 5), and environmental sensor monitoring (temperature,
      humidity, air quality) conducted at participants' homes over 10-day monitoring periods.
  - id: collection-005
    name: Biospecimen collection and biobanking
    description: >
      Blood (53 mL) and urine collected during study visit. Local processing for plasma,
      serum, buffy coats at all sites. Centralized biobanking at UAB CCTS. Standardized
      operating procedures ensure consistent handling.

acquisition_methods:
  - id: acquisition-001
    name: Survey and questionnaire data
    description: >
      Self-reported data collected via REDCap interfaces including demographics, medical
      history, social determinants of health, depression screening (CES-D-10), diabetes-related
      emotional distress (PAID scale), diabetes self-care score, dietary assessment, ophthalmic
      survey, substance use (smoking, alcohol, vaping, marijuana), general health conditions,
      and current medications with RxNorm codes.
  - id: acquisition-002
    name: Physical measurements and vital signs
    description: >
      Height, weight, waist and hip circumference (waist-hip ratio and BMI calculated), blood
      pressure (systolic and diastolic, measured twice separated by 2 minutes), and heart rate
      collected during in-person visit using standardized protocols.
  - id: acquisition-003
    name: Retinal imaging
    description: >
      Multi-device retinal imaging protocol capturing data from Aurora IQ (Optomed), EIDON
      widefield truecolor confocal fundus system (iCare), Spectralis HRA OCT and OCTA
      (Heidelberg Engineering), Maestro2 3D OCT-1 (Topcon), Triton DRI OCT (Topcon),
      Cirrus 5000 (Carl Zeiss), and Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO,
      Heidelberg Engineering). Both eyes imaged under dilated conditions (except Aurora IQ).
      Output formats include DICOM, with proprietary formats (.fda, .sdt) converted to DICOM.
  - id: acquisition-004
    name: Visual function testing
    description: >
      Visual acuity and contrast sensitivity under photopic (daylight) and mesopic (dim light)
      conditions using Electronic Visual Acuity tester (M&S Technology) and Mars chart (Mars
      Perceptrix). Autorefraction data collected using Topcon KR 800.
  - id: acquisition-005
    name: Clinical laboratory testing
    description: >
      Complete blood count (CBC) from fresh whole blood at local CLIA-certified labs. Central
      lab testing at UW Nutrition and Obesity Research Center (NORC) for EDTA plasma tests
      (NT-proBNP, Troponin-T, C-peptide, insulin), serum tests (CRP-HS, lipid panel, glucose,
      kidney and liver function markers), whole blood tests (HbA1c), and urine tests (creatinine,
      albumin, other markers).
  - id: acquisition-006
    name: Electrocardiogram (ECG)
    description: >
      12-lead ECG data collected using Philips Pagewriter TC30 Cardiograph during study visit
      with participant sitting in reclining chair or lying supine at recorded position
      (0째, 30째, 60째, or 90째 relative to supine).
  - id: acquisition-007
    name: Cognitive function testing
    description: >
      Montreal Cognitive Assessment (MoCA) administered electronically on iPad using MoCA Duo
      Application (total score, section subscores, Memory Index Score, task completion times).
      Total possible score is 30, with higher numbers representing better performance.
  - id: acquisition-008
    name: Peripheral neuropathy assessment
    description: >
      Monofilament testing performed to assess peripheral neuropathy using 10g filament at
      three locations on each foot (10 times per location) with participant's eyes closed,
      responding yes/no whether they feel the filament.
  - id: acquisition-009
    name: Continuous glucose monitoring
    description: >
      Dexcom G6 Continuous Glucose Monitor capturing blood glucose measurements (mg/dL) every
      5 minutes for 10 days. Data exported in CSV format.
  - id: acquisition-010
    name: Physical activity monitoring
    description: >
      Garmin VivoSmart 5 wearable device capturing number of steps, heart rate, sleep duration
      (circadian and diurnal rhythm), and oxygen saturation for 10 days. Data exported in .FIT
      format and converted to mHealth standard.
  - id: acquisition-011
    name: Environmental monitoring
    description: >
      Custom-designed environmental sensor (Karalis Johnson Retina Center, UW) capturing ambient
      temperature, relative humidity, nitrogen oxides (NO and NO2), volatile organic compounds,
      particulate matter (PM1.0, PM2.5, PM4, PM10), and multi-spectral light intensity (11
      measurements) for 10 days. Data in CSV format.
  - id: acquisition-012
    name: Biospecimen collection
    description: >
      Non-fasting blood (53 mL) and urine collection. Processing includes whole blood for CBC,
      EDTA plasma, serum, buffy coats for genomic DNA extraction, peripheral blood mononuclear
      cells (PBMCs) from CPT tubes, and PAXgene RNA vacutainers. Samples stored at UAB CCTS
      biorepository at appropriate temperatures.

# Preprocessing, Cleaning, and Labeling
preprocessing_strategies:
  - id: preproc-001
    name: Data standardization and harmonization
    description: >
      Data harmonized across three collection sites (Birmingham, San Diego, Seattle) using
      standardized operating procedures, common protocols, and centralized data management
      through REDCap. Ensures consistency and comparability across sites.
    preprocessing_details:
      - Standardized operating procedures across all three sites
      - Common protocols and equipment
      - Centralized data management through REDCap
      - Standardized training of study coordinators with certification process
      - Manual of Procedures (MOP) for reference
  - id: preproc-002
    name: Image format conversion
    description: >
      Retinal imaging data converted from proprietary formats (.fda, .sdt) to DICOM standard
      for the dataset. Wearable device data converted from .FIT format to mHealth standard.
    preprocessing_details:
      - Proprietary retinal imaging formats (.fda, .sdt) converted to DICOM
      - Wearable device data (.FIT) converted to mHealth standard
      - ECG data exported in .xml format
      - MoCA data exported in .csv format
  - id: preproc-003
    name: Biospecimen processing
    description: >
      Standardized local processing for plasma, serum, and buffy coats using consistent
      protocols. Centralized processing of CPT tubes for PBMC isolation at UAB CCTS. Batch
      shipping of biospecimens for central clinical lab analyses.
    preprocessing_details:
      - Standardized local processing for plasma, serum, buffy coats
      - Centralized PBMC processing at UAB CCTS
      - Batch shipping for central lab analyses at UW NORC
      - Genomic DNA extractions from stored buffy coats performed at UAB CCTS
  - id: preproc-004
    name: Quality control and validation
    description: >
      Multiple quality control measures including standardized training of study coordinators,
      equipment calibration, duplicate measurements, and data validation checks in REDCap
      system. Data managers at each site oversee quality control before uploading to FAIRhub.
    preprocessing_details:
      - Standardized training of study coordinators with certification
      - Equipment calibration protocols
      - Duplicate measurements for quality assurance (e.g., blood pressure measured twice)
      - Data validation checks in REDCap
      - Practice subjects required before enrolling participants
  - id: preproc-005
    name: Data mapping to standards
    description: >
      All data mapped to applicable data standard formats such as Observational Medical Outcomes
      Partnership Common Data Model for clinical data and DICOM format for retinal imaging.
      Data stored and shared as 'AI-ready' enabling immediate AI/ML research without reformatting.
    preprocessing_details:
      - OMOP Common Data Model for clinical data
      - DICOM for retinal imaging
      - mHealth standard for wearable device data
      - RxNorm codes for medications
      - ICD-10 codes for diabetes classification

cleaning_strategies:
  - id: cleaning-001
    name: Multi-site harmonization
    description: >
      Standardized protocols and procedures across all three data collection sites ensure
      data consistency and quality. Common equipment, training, and REDCap data management
      system used to maintain FAIR principles compliance.
    cleaning_details:
      - Cross-site harmonization procedures
      - Standardized equipment and training
      - REDCap data management for quality
      - FAIR principles implementation
      - Pilot enrollment period (July 18 - November 30, 2023) to ensure coordinator familiarity

# Uses
intended_uses:
  - id: use-001
    name: AI/ML model development for T2DM
    description: >
      Primary intended use is development and training of artificial intelligence and machine
      learning models to study Type 2 Diabetes Mellitus, disease trajectories, and salutogenesis
      (pathways to health resilience). Designed for pseudotime manifold analysis to predict
      disease progression.
  - id: use-002
    name: Multi-modal T2DM research
    description: >
      Research leveraging multiple data domains (imaging, clinical, genomic, wearable,
      environmental, survey) to understand complex interactions and relationships in T2DM
      progression and management.
  - id: use-003
    name: Health equity research
    description: >
      Studies examining racial and ethnic disparities in T2DM outcomes, social determinants
      of health effects, and development of equitable AI/ML applications for diverse populations.
  - id: use-004
    name: Biomarker discovery
    description: >
      Discovery of novel biomarkers for T2DM progression, complications, and salutogenesis
      using biospecimens from the biorepository.
  - id: use-005
    name: Model dataset for AI-ready data standards
    description: >
      Use as an exemplar for future AI-ready medical dataset development, demonstrating best
      practices in data collection, preparation, sharing, and ethical governance.

discouraged_uses:
  - id: discouraged-001
    name: Uses during ongoing enrollment
    description: >
      As enrollment is ongoing until November 2026, pilot data releases and periodic updates
      may not have achieved balanced distribution across all groups. Early versions should be
      used with awareness of this limitation.
  - id: discouraged-002
    name: Clinical decision-making without validation
    description: >
      Dataset is for research purposes. Any AI/ML models developed should undergo appropriate
      clinical validation before use in patient care or clinical decision-making.
  - id: discouraged-003
    name: Re-identification attempts
    description: >
      Attempts to re-identify participants from de-identified data violate ethical principles
      and data use agreements.

# Distribution
license: CC BY-NC 4.0
license_and_use_terms:
  id: license-001
  name: Creative Commons Attribution Non-Commercial
  description: >
    Public access data distributed under Creative Commons Attribution Non-Commercial (CC BY-NC 4.0)
    license. Permits others to distribute, remix, adapt, build upon this work non-commercially,
    and license their derivative works on different terms, provided the original work is properly
    cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
    Controlled access data requires data use agreement. See http://creativecommons.org/licenses/by-nc/4.0/
    for full license terms.
  license_terms:
    - Proper citation required
    - Non-commercial use only for public data
    - Derivative works permitted with attribution
    - Changes must be indicated
    - Controlled access data requires separate data use agreement

distribution_formats:
  - id: format-001
    name: DICOM for imaging
    description: >
      Retinal imaging data distributed in DICOM format (converted from proprietary .fda and
      .sdt formats for standardization).
    access_urls:
      - https://fairhub.io/datasets/2
  - id: format-002
    name: CSV for tabular and time-series data
    description: >
      Survey data, clinical lab results, continuous glucose monitoring, environmental sensor
      data, and other tabular/time-series data provided in CSV format.
    access_urls:
      - https://fairhub.io/datasets/2
  - id: format-003
    name: mHealth standard for wearable data
    description: >
      Physical activity monitoring data (from Garmin VivoSmart 5) converted from .FIT format
      to mHealth standard for interoperability.
    access_urls:
      - https://fairhub.io/datasets/2
  - id: format-004
    name: REDCap data dictionary
    description: >
      Metadata and data dictionaries provided through REDCap system documentation for survey
      and study coordination data.
    access_urls:
      - https://docs.aireadi.org/

# Maintenance
maintainers:
  - id: maintainer-001
    name: AI-READI Consortium
    description: >
      Multidisciplinary consortium managing dataset maintenance including data collection sites,
      coordinating centers, and data governance committees.
    maintainer_details:
      - University of Washington (lead institution, data coordination)
      - University of Alabama at Birmingham (biorepository, data collection)
      - University of California San Diego (data collection)
      - Data Access Committee (access policies)
      - Documentation team (version-specific guides at https://docs.aireadi.org/)

updates:
  id: updates-001
  name: Periodic data releases and maintenance plan
  description: >
    Dataset updated periodically as enrollment progresses toward target of 4,000 participants
    by November 2026. Version-specific documentation maintained for each release. Biorepository
    maintained at UAB CCTS with long-term storage protocols. Data sharing policies under ongoing
    development by Data Access Committee. Pilot data released May 2024; all data through July 31,
    2024 released November 2024.
  frequency: Periodic releases with ongoing enrollment; final release planned for late 2026
  update_details:
    - Periodic data releases as enrollment continues
    - Pilot data released May 2024
    - v1.0.0 data through July 31, 2024 released November 2024
    - v2.0.0 and v3.0.0 released with additional participants
    - Final dataset expected after completion of 4,000 participant enrollment by November 2026
    - Dataset versioning implemented
    - Version-specific documentation at https://docs.aireadi.org/

retention_limit:
  id: retention-001
  name: Data and biospecimen retention
  description: >
    Digital data maintained according to NIH data sharing policies. Biospecimen retention
    subject to institutional policies and consent agreements. Finite number of biospecimen
    samples available for distribution.
  retention_details:
    - NIH data sharing policies govern digital data retention
    - Biospecimen retention per institutional policies at UAB CCTS
    - Consent agreements specify retention terms
    - Finite biospecimen availability
    - Procedures for reviewing and prioritizing biospecimen requests under development

# Ethics and Human Subjects
human_subject_research:
  id: hsr-001
  name: AI-READI Human Subjects Research
  description: >
    Study approved by Institutional Review Board (IRB) of University of Washington (approval
    number STUDY00016228), with reliance agreements from IRBs of University of Alabama at
    Birmingham and University of California, San Diego. Written informed consent provided
    by all participants. Bioethics guidance integrated throughout study design. Community
    Advisory Board of 11 persons with diversity in race and ethnicity contributes to protocol
    development. Ethical and equitable data collection and management practices implemented.
  involves_human_subjects: true
  irb_approval:
    - University of Washington IRB approval number STUDY00016228
    - University of Alabama at Birmingham IRB reliance agreement
    - University of California San Diego IRB reliance agreement
  ethics_review_board:
    - University of Washington Institutional Review Board
    - University of Alabama at Birmingham Institutional Review Board (reliance agreement)
    - University of California San Diego Institutional Review Board (reliance agreement)
    - Community Advisory Board with 11 members representing diverse race and ethnicity
  special_populations:
    - Recruitment targeted to include racial and ethnic minorities disproportionately affected by T2DM
    - Asian populations
    - Black populations
    - Hispanic populations
    - Tribal consultation planned for Native American cohort participation

sensitive_elements:
  - id: sensitive-001
    name: Genetic and biospecimen data
    description: >
      Genomic DNA extracted from buffy coats, blood derivatives, and urine samples stored
      with potential for future genetic analyses. Available in controlled access dataset only.
    sensitive_elements_present: true
    sensitivity_details:
      - Genetic sequencing data from buffy coats
      - Blood derivatives and urine biospecimens
      - Peripheral blood mononuclear cells (PBMCs)
      - PAXgene RNA
  - id: sensitive-002
    name: Geographic and demographic identifiers
    description: >
      5-digit zip code, detailed race, ethnicity, and sex information available in controlled
      access dataset only. Public dataset contains de-identified data.
    sensitive_elements_present: true
    sensitivity_details:
      - 5-digit zip code
      - Race and ethnicity details
      - Biological sex
  - id: sensitive-003
    name: Medical history and records
    description: >
      Past health records, medications, traffic and accident reports available in controlled
      access dataset only.
    sensitive_elements_present: true
    sensitivity_details:
      - Past health records
      - Medications with RxNorm codes
      - Traffic and accident reports

# Data Governance and External Resources
external_resources:
  - id: resource-001
    name: AI-READI Project Website
    description: Official project website with overview and resources
    external_resources:
      - https://aireadi.org/
  - id: resource-002
    name: AI-READI Dataset Documentation
    description: Comprehensive dataset documentation with version-specific guides
    external_resources:
      - https://docs.aireadi.org/
  - id: resource-003
    name: FAIRhub Dataset Landing Page
    description: Dataset repository and download portal
    external_resources:
      - https://fairhub.io/datasets/2
  - id: resource-004
    name: Bridge2AI Program
    description: Parent NIH Common Fund program supporting AI-ready biomedical datasets
    external_resources:
      - https://bridge2ai.org/
  - id: resource-005
    name: NIH RePORTER Project Details
    description: Federal grant information and project details
    external_resources:
      - https://reporter.nih.gov/project-details/10471118
  - id: resource-006
    name: Data Sharing Information
    description: Policies and procedures for data access
    external_resources:
      - https://aireadi.org/goals/data-sharing
  - id: resource-007
    name: Zenodo Archive
    description: Additional dataset documentation and resources
    external_resources:
      - https://doi.org/10.5281/zenodo.10642459
  - id: resource-008
    name: Protocol Publication (BMJ Open)
    description: BMJ Open publication describing study design and protocol
    external_resources:
      - https://doi.org/10.1136/bmjopen-2024-097449
  - id: resource-009
    name: Nature Metabolism Commentary
    description: Overview of AI-READI approach and significance
    external_resources:
      - https://doi.org/10.1038/s42255-024-01165-x
